SCYNEXIS Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.19.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of SCYNEXIS Inc is 9.30, ranking 6 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 295.08%.
Key Metrics
The current valuation score of SCYNEXIS Inc is 7.64, ranking 53 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -1.54, which is -371.12% below the recent high of 4.17 and -318.77% above the recent low of -6.44.
The current earnings forecast score of SCYNEXIS Inc is 8.67, ranking 12 out of 155 in the Pharmaceuticals industry. The average price target is 4.00, with a high of 4.00 and a low of 3.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of SCYNEXIS Inc is 6.00, ranking 132 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.00 and the support level at 0.60, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of SCYNEXIS Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 25.24%, representing a quarter-over-quarter decrease of 22.57%. The largest institutional shareholder is James Simons, holding a total of 224.64K shares, representing 0.28% of shares outstanding, with 29.98% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of SCYNEXIS Inc is 3.19, ranking 105 out of 155 in the Pharmaceuticals industry. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
